The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial.
 
Padmanee Sharma
Stock and Other Ownership Interests - Achelois Oncology; Achelois Oncology (I); Adaptive Biotechnologies; Adaptive Biotechnologies (I); Affini-T Therapeutics; Affini-T Therapeutics (I); Apricity Health; Apricity Health (I); BioAtla; BioAtla (I); BioNTech; BioNTech (I); Candel Therapeutics; Candel Therapeutics (I); Catalio; Codiak Biosciences; Codiak Biosciences (I); Dragonfly Therapeutics; Dragonfly Therapeutics (I); Earli; Earli (I); Enable Medicine; Enable Medicine (I); Glympse Bio; Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Infinity Pharmaceuticals; InterVenn Biosciences; InterVenn Biosciences (I); JSL Health; Lava Therapeutics; Lava Therapeutics (I); Lytix Biopharma; Lytix Biopharma (I); Marker Therapeutics; Marker Therapeutics (I); Oncolytics; PBM Capital; PBM Capital (I); Phenomic AI; Phenomic AI (I); Polaris; Polaris (I); Sporos Bio; Time Bioventures; Trained Therapeutix Discovery; Trained Therapeutix Discovery (I); Two Bear Capital; Two Bear Capital (I)
Consulting or Advisory Role - Achelois Oncology; Achelois Oncology (I); Affini-T Therapeutics; Apricity Health; Apricity Health (I); Asher Biotherapeutics; BioAtla; BioAtla (I); C-Reveal Therapeutics; Candel Therapeutics; Candel Therapeutics (I); Carisma Therapeutics; Catalio; Codiak Biosciences; Codiak Biosciences (I); Dragonfly Therapeutics; Dragonfly Therapeutics (I); Earli; Earli (I); Enable Medicine; Enable Medicine (I); Glympse Bio; Henlius; Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Infinity Pharmaceuticals; InterVenn Biosciences; Lava Therapeutics; Lava Therapeutics (I); Lytix Biopharma; Lytix Biopharma (I); Marker Therapeutics; Marker Therapeutics (I); Oncolytics; PBM Capital; PBM Capital (I); Phenomic AI; Phenomic AI (I); Polaris; Polaris (I); Trained Therapeutix Discovery; Trained Therapeutix Discovery (I); Two Bear Capital; Two Bear Capital (I); Xilis
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I)
 
Michael Krainer
No Relationships to Disclose
 
Fred Saad
Honoraria - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; BMS; Janssen Oncology; Knight Therapeutics; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Knight Therapeutics; Myovant Sciences; Novartis; Pfizer; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
Daniel Castellano
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sanofi; Sanofi
Research Funding - Janssen Oncology (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Bristol-Myers Squibb; Pfizer; Roche
 
Jens Bedke
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck KGaA; MSD Oncology; Pfizer; Pfizer; Roche
Speakers' Bureau - Bristol-Myers Squibb; Ipsen; Merck KGaA; MSD Oncology; Pfizer
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst); Seagen (Inst)
 
Mariusz Kwiatkowski
No Relationships to Disclose
 
Akash Patnaik
Stock and Other Ownership Interests - Gilead Sciences; Infinity Pharmaceuticals; Merck; Merck
Honoraria - Medscape; Prime Oncology
Consulting or Advisory Role - Curio Science; Exelixis; Gerson Lehrman Group; Guidepoint Pharmacy
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Laekna Health Care (Inst); Progenics (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Exelixis; Prime Oncology
 
Giuseppe Procopio
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb (BMS); Eisai; Ipsen; Janssen; Merck Sharp & Dohme; MSD Oncology; Novartis; Pfizer
Research Funding - Astellas Pharma; Ipsen; Janssen Oncology
 
Pawel Wiechno
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen-Cilag; Merck; MSD; MSD; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen-Cilag; Merck; Pfizer
Travel, Accommodations, Expenses - Astellas Pharma; Pfizer
 
Samith Thomas Kochuparambil
No Relationships to Disclose
 
Christian Thomas
Stock and Other Ownership Interests - Orion Biotechnology
Honoraria - Astellas Pharma; Janssen Oncology
Consulting or Advisory Role - BMSi; Janssen Oncology; MSD Oncology
Travel, Accommodations, Expenses - Janssen Oncology
 
Jose Angel Arranz Arija
Honoraria - Astellas Pharma; BMS; Pfizer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Eisai; Janssen-Cilag; Merck; MSD Oncology; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst)
 
Steven L. McCune
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Roche/Genentech
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb; Roche/Genentech
Other Relationship - Roche (Inst)
 
Steinbjorn Hansen
No Relationships to Disclose
 
Gedske Daugaard
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb/Pfizer; Enterome; MSD Oncology; Pfizer; Sanofi/Aventis
Travel, Accommodations, Expenses - Astellas Pharma
 
Neha P. Amin
Employment - AstraZeneca; Bristol Myers Squibb
Stock and Other Ownership Interests - AstraZeneca; Bristol Myers Squibb
Travel, Accommodations, Expenses - AstraZeneca; Bristol Myers Squibb
 
Yumeng Wang
Employment - Bristol-Myers Squibb; Novartis
 
Justin M. David
Employment - Bristol Myers Squibb
Stock and Other Ownership Interests - Bristol Myers Squibb
 
Russell Kent Pachynski
Consulting or Advisory Role - Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Dendreon; EMD Serono; Genomic Health; Jounce Therapeutics; Pfizer/EMD Serono; Sanofi
Speakers' Bureau - AstraZeneca; Dendreon; Genentech/Roche; Genomic Health; Merck; Sanofi
Research Funding - Bristol Myers Squibb Foundation (Inst); Exelixis (Inst); Janssen Oncology; Pharmacyclics (Inst)
Patents, Royalties, Other Intellectual Property - Entitled: METHOD OF CELL-FREE DNA ANALYSIS TO IDENTIFY HIGH-RISK METASTATIC PROSTATE CANCER
Travel, Accommodations, Expenses - Genentech/Roche